INMB

INmune Bio (INMB)

About INmune Bio (INMB)

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

Details

Daily high
$1.50
Daily low
$1.41
Price at open
$1.41
52 Week High
$11.64
52 Week Low
$1.09
Market cap
38.0M
Dividend yield
0.00%
Volume
240,373
Avg. volume
249,627
P/E ratio
-.74

INmune Bio News

Details

Daily high
$1.50
Daily low
$1.41
Price at open
$1.41
52 Week High
$11.64
52 Week Low
$1.09
Market cap
38.0M
Dividend yield
0.00%
Volume
240,373
Avg. volume
249,627
P/E ratio
-.74